Drugs for Unmet Needs May Get Faster Approval Under Senate Plan

Congressional talks to renew the fees drugmakers pay to fund Food and Drug Administration reviews include proposals to fast-track evaluations of medicines for conditions with no approved cures, according to two U.S. Senate aides.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.